GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRDF · Mar 31, 2026

Cardiff Oncology, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001213037-26-000011General Corporate
Operating cash generation0thOwn-history percentile · N=15
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-29970.73% · OPTIONAL · VALID

Revenue growth0thOwn-history percentile · N=11
Evidence method

Yoy · gp.fundamentals.revenue

-62.39% · CORE · VALID

Operating margin0thOwn-history percentile · N=15
Evidence method

Level · gp.fundamentals.operating_margin

-31341.46% · CORE · VALID

SBC intensity100thOwn-history percentile · N=15
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4048.78% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-6395.11%
Current
-29970.73%
Delta
-23575.62%
Growth Decreased
Previous
-13.18%
Current
-62.39%
Delta
-49.21%
Profitability Decreased
Previous
-8256.32%
Current
-31341.46%
Delta
-23085.14%
Sbc Intensity Increased
Previous
960.03%
Current
4048.78%
Delta
3088.75%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.